The brain of a woman who died after receiving a new Alzheimers disease drug has deepened some researchers’ concerns that lecanemab poses serious risks for patients.
A full autopsy and detailed examination of the brain of a 79-year-old Florida woman who died after receiving lecanemab, an experimental Alzheimer’s therapy, in a pivotal clinical trial has deepened some researchers’ concerns that it poses serious risks for patients who share the woman’s hard-to-diagnose, preexisting condition.
The case report and the experts’ recommendations are likely to be hot topics at an FDA advisory panel meeting on the drug, which the agency this week said would be on 9 June. The panel will assess the drug’s pros and cons before FDA makes its final decision on full approval, likely in July. But the drug, now marketed as Leqembi by its maker Eisai Co., has also been linked to several deaths and brain injuries, as well as to a reduction in brain volume, during its trials or their extensions. The case report, currently under review at a journal, expands on an earlier
Besides weakening blood vessel walls, lecanemab and other antiamyloid antibodies may pose another hazard to people with CAA, Harmsen, Schrag, and their colleagues say. As the antibodies remove clumps of amyloid from brain tissue, the agglomerations may clog blood vessels and lead to “an inflammatory cascade” that increases the risk of life-threatening swelling and bleeding.
The authors of the case report say that’s not enough. “This case should prompt a careful evaluation of the safety of lecanemab treatment and a refinement of the approach to pre-screening potential recipients of lecanemab for [CAA],” they conclude. The group wrote that Alzheimer’s patients with probable CAA and related brain inflammation, as indicated by brain imaging, should not receive lecanemab. Villain calls that proposal too weak. He and colleagues wrote in anof recommendations—for the use of antiamyloid antibodies in France—that any Alzheimer’s patients with probable CAA, even those without evidence of brain inflammation, should not receive lecanemab.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pitch deck clinical trials startup Inato used to get $20 millionSee the 16-slide presentation a startup used to sell investors on a new approach to solving a $50 billion problem for Big Pharma
Read more »
Ongoing Adderall shortage has Houston doctors and patients still struggling to find ADHD medicationIt's been six months since the FDA announced a nationwide shortage of Adderall, and...
Read more »
Ghana first to approve 'world-changer' malaria vaccineThe vaccine - R21 - was up to 80% effective in early-stage clinical trials.
Read more »
Court Partially Halts Ruling Restricting Access to Abortion PillA hardline conservative judge suspended the FDA’s approval of the drug last Friday.
Read more »
Health Misinformation Is Lowering U.S. Life Expectancy, FDA Official SaysThe U.S. life expectancy is three to five years lower than that of peer countries.
Read more »
How an abortion pill ruling could threaten the FDA's regulatory authorityA medical ethics expert says a Texas abortion pill ruling is unprecedented because a federal judge 'standing in' for regulators could have far-reaching implications beyond mifepristone.
Read more »